Hospitalizations for aplastic anemia and agranulocytosis in Saskatchewan: incidence and associations with antecedent prescription drug use.

作者: Leah Lueck , Nigel S.B. Rawson , Sheila Rutledge Harding , Edith Malcolm

DOI: 10.1016/S0895-4356(98)00072-9

关键词: LeukopeniaPopulationIncidence (epidemiology)Intensive care medicineAplastic anemiaSulfasalazinePrescription drugProcainamideNeutropeniaPediatricsMedicine

摘要: A population-based study to estimate the incidence of hospitalizations for aplastic anemia and agranulocytosis evaluate associations between these disorders antecedent prescription drug use was performed using Saskatchewan administrative health care databases. Hospital charts cancer registration data were utilized apply strict diagnostic criteria case identification. Estimates annual 2.7 3.0 per million, which are similar those from other recent studies with comparable identification criteria. Only a small number cases available potential causes, leading an analysis limited power. Nevertheless, significant found tocainide, gold salts, antidepressants; anti-thyroids, trimethoprim-sulfamethoxazole, β-lactams, sulfasalazine, chlorpromazine, carbamazepine, glyburide, procainamide, although antibiotics may indicate response rather than possible cause. These findings generally consistent results case-control investigations.

参考文章(118)
Brian L Strom, Jeffrey L Carson, Rita Schinnar, Ellen Sim Snyder, Michele Shaw, Frank E Lundin, Nonsteroidal Anti-inflammatory Drugs and Neutropenia Archives of Internal Medicine. ,vol. 153, pp. 2119- 2124 ,(1993) , 10.1001/ARCHINTE.1993.00410180065007
Judith P Kelly, David W Kaufman, Samuel Shapiro, Risks of agranulocytosis and aplastic anemia in relation to the use of cardiovascular drugs: The International Agranulocytosis and Aplastic Anemia Study Clinical Pharmacology and Therapeutics. ,vol. 49, pp. 330- 341 ,(1991) , 10.1038/CLPT.1991.37
Gerald A. Faich, Analgesic risks and pharmacoepidemiology. JAMA. ,vol. 256, pp. 1788- 1788 ,(1986) , 10.1001/JAMA.1986.03380130116040
Norton D. Ritz, AGRANULOCYTOSIS DUE TO ADMINISTRATION OF SALICYLAZOSULFAPYRIDINE (AZULFIDINE) Journal of the American Medical Association. ,vol. 172, pp. 237- 240 ,(1960) , 10.1001/JAMA.1960.63020030002008A
L. M. E. Williame, R. Joos, F. Proot, C. Immesoete, Gold- induced aplastic anemia Clinical Rheumatology. ,vol. 6, pp. 600- 605 ,(1987) , 10.1007/BF02330601
A G Kay, Myelotoxicity of gold. BMJ. ,vol. 1, pp. 1266- 1268 ,(1976) , 10.1136/BMJ.1.6020.1266
Richard I.H. Wang, Gert Schuller, Agranulocytosis following procainamide administration American Heart Journal. ,vol. 78, pp. 282- 284 ,(1969) , 10.1016/0002-8703(69)90024-6
Ivan K. Rothman, Procainamide-Induced Agranulocytosis and Thrombocytopenia Archives of Internal Medicine. ,vol. 139, pp. 246- 247 ,(1979) , 10.1001/ARCHINTE.1979.03630390096035